TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Compensatory Movements in Stroke Therapy Through the Use of Robotic Devices and Augmented Feedback, 3rd Phase
Brief Summary: The project targets stroke survivors to investigate the effect of augmented feedback (using robotic force cues and visual feedback) and rewards (game scores), on their upper limb reaching patterns and trunk compensatory movements


Options:
A: Arm Label: Measurements and T-chair training; Type: EXPERIMENTAL; Interventions: Device: T-chair | Arm Label: Measurements; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: T-chair; Assigned to Arm(s): Measurements and T-chair training
B: Arm Label: Start with Visual + Force; Type: EXPERIMENTAL; Interventions: Other: Visual + Force Feedback, Other: Visual + Force + Game Scores Feedback | Arm Label: Start with Visual + Force + Game Scores; Type: EXPERIMENTAL; Interventions: Other: Visual + Force Feedback, Other: Visual + Force + Game Scores Feedback | Intervention Type: OTHER; Name: Visual + Force Feedback; Assigned to Arm(s): Start with Visual + Force, Start with Visual + Force + Game Scores | Intervention Type: OTHER; Name: Visual + Force + Game Scores Feedback; Assigned to Arm(s): Start with Visual + Force, Start with Visual + Force + Game Scores
C: Arm Label: IMT & EMT; Type: EXPERIMENTAL; Interventions: Other: Respiratory muscle training for EMT+IMT, Other: Regular Rehabilitation | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Regular Rehabilitation | Arm Label: EMT group; Type: EXPERIMENTAL; Interventions: Other: Regular Rehabilitation, Other: Respiratory muscle training for EMT | Intervention Type: OTHER; Name: Respiratory muscle training for EMT+IMT; Assigned to Arm(s): IMT & EMT | Intervention Type: OTHER; Name: Regular Rehabilitation; Assigned to Arm(s): Control group, EMT group, IMT & EMT | Intervention Type: OTHER; Name: Respiratory muscle training for EMT; Assigned to Arm(s): EMT group
D: Arm Label: Semi-immersive virtual reality; Type: EXPERIMENTAL; Interventions: Other: Semi-immersive virtual reality | Arm Label: Conventional Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Rehabilitation | Intervention Type: OTHER; Name: Semi-immersive virtual reality; Assigned to Arm(s): Semi-immersive virtual reality | Intervention Type: OTHER; Name: Conventional Rehabilitation; Assigned to Arm(s): Conventional Rehabilitation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Brief Summary: Assess the efficacy and safety of ruxolitinib compared to Best Available Therapy (BAT) in patients with corticosteroid-refractory acute graft vs. host disease (aGvHD) after allogeneic stem cell transplantation.


Options:
A: Arm Label: TBI + fludarabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conditioning regimen: TBI + Fludarabine | Arm Label: TLI + ATG; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conditioning regimen:TLI (8 Gy) + ATG | Intervention Type: DRUG; Name: Conditioning regimen: TBI + Fludarabine; Assigned to Arm(s): TBI + fludarabine | Intervention Type: DRUG; Name: Conditioning regimen:TLI (8 Gy) + ATG; Assigned to Arm(s): TLI + ATG
B: Arm Label: routine prophylaxis; Type: ACTIVE_COMPARATOR; Interventions: Drug: anti thymoglobulin | Arm Label: ATG prophylaxis; Type: EXPERIMENTAL; Interventions: Drug: anti thymoglobulin | Intervention Type: DRUG; Name: anti thymoglobulin; Assigned to Arm(s): ATG prophylaxis, routine prophylaxis
C: Arm Label: ATG-F; Type: EXPERIMENTAL; Interventions: Drug: ATG-Fresenius S | Arm Label: non-ATG-F; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: ATG-Fresenius S; Assigned to Arm(s): ATG-F
D: Arm Label: Ruxolitinib; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib (RUX) | Arm Label: Best Available Therapy (BAT); Type: ACTIVE_COMPARATOR; Interventions: Drug: Best Available Therapy (BAT) | Intervention Type: DRUG; Name: Ruxolitinib (RUX); Assigned to Arm(s): Ruxolitinib | Intervention Type: DRUG; Name: Best Available Therapy (BAT); Assigned to Arm(s): Best Available Therapy (BAT)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RE-SPECT CVT: a Randomised, Open-label, Exploratory Trial With Blinded Endpoint Adjudication (PROBE), Comparing Efficacy and Safety of Oral Dabigatran Etexilate Versus Oral Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis Over a 24-week Period
Brief Summary: This is a multi-center, prospective, international, randomized (1:1), open-label study with two parallel groups. This phase III study is planned to investigate the efficacy and safety of dabigatran etexilate versus dose-adjusted warfarin on a net clinical benefit endpoint of major bleeding (ISTH criteria) and new venous thrombotic event (VTE) (primary endpoint) with blinded endpoint adjudication.


Options:
A: Arm Label: Dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran etexilate | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran etexilate; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin
B: Arm Label: Heparin; Type: EXPERIMENTAL; Interventions: Drug: Heparin, Drug: Placebo | Arm Label: Nadroparin; Type: EXPERIMENTAL; Interventions: Drug: Nadroparin, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Heparin, Drug: Nadroparin | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Heparin, Placebo | Intervention Type: DRUG; Name: Nadroparin; Assigned to Arm(s): Nadroparin, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Heparin, Nadroparin
C: Arm Label: Dabigatran therapy; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran | Arm Label: Acetylsalicylic Acid thereapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran therapy | Intervention Type: DRUG; Name: Acetylsalicylic acid; Assigned to Arm(s): Acetylsalicylic Acid thereapy
D: Arm Label: Apixaban; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exercise and Intensive Vascular Risk Reduction in Preventing Dementia
Brief Summary: Physical inactivity, high blood pressure and dyslipidemia are risk factors for Alzheimer's disease (AD) and vascular dementia. Importantly, these risk factors are modifiable with lifestyle changes, pharmacological treatment, or both. The rrAD study will determine effects of aerobic exercise training and intensive vascular risk reduction on cognitive performance in older adults who have high risk for AD.


Options:
A: Arm Label: Intensive; Type: EXPERIMENTAL; Interventions: Other: Anti-hypertensive therapy to SBP 130 mm Hg | Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Anti-hypertensive therapy to SBP 145 mm Hg | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 130 mm Hg; Assigned to Arm(s): Intensive | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 145 mm Hg; Assigned to Arm(s): Standard
B: Arm Label: Aerobic Exercise (Ex); Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise Training, Other: Usual Care | Arm Label: Intensive Reduction of Vascular Risk Factors (IRVR); Type: EXPERIMENTAL; Interventions: Drug: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine), Behavioral: Stretching Exercise | Arm Label: IRVR+Ex; Type: EXPERIMENTAL; Interventions: Drug: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine), Behavioral: Aerobic Exercise Training | Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual Care, Behavioral: Stretching Exercise | Intervention Type: DRUG; Name: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine); Assigned to Arm(s): IRVR+Ex, Intensive Reduction of Vascular Risk Factors (IRVR) | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Training; Assigned to Arm(s): Aerobic Exercise (Ex), IRVR+Ex | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Aerobic Exercise (Ex), Usual Care | Intervention Type: BEHAVIORAL; Name: Stretching Exercise; Assigned to Arm(s): Intensive Reduction of Vascular Risk Factors (IRVR), Usual Care
C: Arm Label: A,1,IV; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin | Arm Label: A,2,IV; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin | Arm Label: A,3,IV; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin | Arm Label: A,4,IV; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin | Intervention Type: DRUG; Name: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin; Assigned to Arm(s): A,1,IV, A,2,IV, A,3,IV, A,4,IV
D: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Recent studies showed the benefits of early initiation and advancement enteral feeds with daily increments in preterm infants on decreasing invasive infections and early achievement of full enteral feedings. But the data on enteral feeds of extremely low birthweight infants are limited. Preterm infants especially those \<1250 gr birthweight are at increased risk of developing feeding intolerance and necrotizing enterocolitis (NEC) and so the initiation and the rate of increments of enteral feeds are usually uncertain issues for neonatologists.


Options:
A: Arm Label: probiotic group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus reuteri | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus reuteri; Assigned to Arm(s): probiotic group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium bifidum supplementation | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo contains dextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium bifidum supplementation; Assigned to Arm(s): Active | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo contains dextrin; Assigned to Arm(s): Placebo
C: Arm Label: group 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: nutrition | Arm Label: group 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: nutrition | Intervention Type: DIETARY_SUPPLEMENT; Name: nutrition; Assigned to Arm(s): group 1, group 2
D: Arm Label: probiotics group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: probiotics | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: glucose solution | Intervention Type: DIETARY_SUPPLEMENT; Name: probiotics; Assigned to Arm(s): probiotics group | Intervention Type: DIETARY_SUPPLEMENT; Name: glucose solution; Assigned to Arm(s): control group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mass Drug Administration of Monthly DHA-PQP to Accelerate Towards Malaria Elimination in Magude District, Southern Mozambique
Brief Summary: In line with the global and regional efforts towards malaria elimination, a five year program was established to assist the NMCP in adopting targeted evidence-based elimination plans through a 'learn by doing' strategy. The project aims to generate knowledge as data is generated to inform the programmatic aspects of the elimination plan, most importantly how to clear malaria parasites from the asymptomatic reservoir.


Options:
A: Arm Label: MDA with DHAp (Eurartesim); Type: EXPERIMENTAL; Interventions: Drug: MDA with DHAp (Eurartesim) | Arm Label: Focal MDA with DHAp (Eurartesim); Type: EXPERIMENTAL; Interventions: Drug: Focal MDA with DHAp (Eurartesim) | Arm Label: Standard of Care (Control); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: MDA with DHAp (Eurartesim); Assigned to Arm(s): MDA with DHAp (Eurartesim) | Intervention Type: DRUG; Name: Focal MDA with DHAp (Eurartesim); Assigned to Arm(s): Focal MDA with DHAp (Eurartesim)
B: Arm Label: MDA with DHAp and SLD Primaquine; Type: EXPERIMENTAL; Interventions: Drug: MDA with DHAp and SLD Primaquine | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: MDA with DHAp and SLD Primaquine; Assigned to Arm(s): MDA with DHAp and SLD Primaquine
C: Arm Label: Participants; Type: OTHER; Interventions: Drug: Dihydroartemisinin-piperaquine | Intervention Type: DRUG; Name: Dihydroartemisinin-piperaquine; Assigned to Arm(s): Participants
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg), Drug: Artesunate (day 1,2,3: 4 mg/kg), Drug: Primaquine-base (day 3: 0.75 mg/kg) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablets | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Artesunate (day 1,2,3: 4 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Primaquine-base (day 3: 0.75 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo tablets; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mass Drug Administration of Monthly DHA-PQP to Accelerate Towards Malaria Elimination in Magude District, Southern Mozambique
Brief Summary: In line with the global and regional efforts towards malaria elimination, a five year program was established to assist the NMCP in adopting targeted evidence-based elimination plans through a 'learn by doing' strategy. The project aims to generate knowledge as data is generated to inform the programmatic aspects of the elimination plan, most importantly how to clear malaria parasites from the asymptomatic reservoir.


Options:
A: Arm Label: Participants; Type: OTHER; Interventions: Drug: Dihydroartemisinin-piperaquine | Intervention Type: DRUG; Name: Dihydroartemisinin-piperaquine; Assigned to Arm(s): Participants
B: Arm Label: IRS; Type: EXPERIMENTAL; Interventions: Other: Actellic CS | Arm Label: non-IRS; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Actellic CS; Assigned to Arm(s): IRS
C: Arm Label: LLIN plus IRS; Type: EXPERIMENTAL; Interventions: Other: Indoor residual spraying with bendiocarb, Other: LLIN by universal coverage campaign | Arm Label: LLIN only; Type: ACTIVE_COMPARATOR; Interventions: Other: LLIN by universal coverage campaign | Intervention Type: OTHER; Name: Indoor residual spraying with bendiocarb; Assigned to Arm(s): LLIN plus IRS | Intervention Type: OTHER; Name: LLIN by universal coverage campaign; Assigned to Arm(s): LLIN only, LLIN plus IRS
D: Arm Label: RACD without RAVC; Type: EXPERIMENTAL; Interventions: Combination Product: RACD | Arm Label: RACD+RAVC; Type: EXPERIMENTAL; Interventions: Combination Product: RACD, Combination Product: RAVC | Arm Label: rfMDA without RAVC; Type: EXPERIMENTAL; Interventions: Combination Product: RAVC, Combination Product: rfMDA | Arm Label: rfMDA+RAVC; Type: EXPERIMENTAL; Interventions: Combination Product: rfMDA | Intervention Type: COMBINATION_PRODUCT; Name: RACD; Assigned to Arm(s): RACD without RAVC, RACD+RAVC | Intervention Type: COMBINATION_PRODUCT; Name: RAVC; Assigned to Arm(s): RACD+RAVC, rfMDA without RAVC | Intervention Type: COMBINATION_PRODUCT; Name: rfMDA; Assigned to Arm(s): rfMDA without RAVC, rfMDA+RAVC

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Brief Summary: The purpose of this study is to evaluate the clinical consistency of three production lots of the Porcine circovirus (PCV)-free liquid formulation of oral live attenuated human rotavirus (HRV) vaccine and to evaluate the PCV-free liquid formulation of HRV vaccine as compared to the currently licensed lyophilised formulation of the HRV vaccine in terms of immunogenicity, reactogenicity and safety when administered as a two-dose vaccination in healthy infants starting at age 6-12 weeks. No new subjects will be enrolled in the extension phase of the study.


Options:
A: Intervention Type: BIOLOGICAL; Name: HRV vaccine; Assigned to Arm(s): N/A
B: Arm Label: Rotavin2H; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin2L; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin3H; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin3L; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotavin2H, Rotavin2L, Rotavin3H, Rotavin3L
C: Arm Label: Group 1 - BRV-PV Lot A; Type: EXPERIMENTAL; Interventions: Biological: BRV-PV Lot A + DPT-HepB-Hib + OPV | Arm Label: Group 2 - BRV-PV Lot B; Type: EXPERIMENTAL; Interventions: Biological: BRV-PV Lot B + DPT-HepB-Hib + OPV | Arm Label: Group 3 - BRV-PV Lot C; Type: EXPERIMENTAL; Interventions: Biological: BRV-PV Lot C + DPT-HepB-Hib + OPV | Arm Label: Group 4 - ROTARIX; Type: ACTIVE_COMPARATOR; Interventions: Biological: ROTARIX + DPT-HepB-Hib + OPV | Intervention Type: BIOLOGICAL; Name: BRV-PV Lot A + DPT-HepB-Hib + OPV; Assigned to Arm(s): Group 1 - BRV-PV Lot A | Intervention Type: BIOLOGICAL; Name: BRV-PV Lot B + DPT-HepB-Hib + OPV; Assigned to Arm(s): Group 2 - BRV-PV Lot B | Intervention Type: BIOLOGICAL; Name: BRV-PV Lot C + DPT-HepB-Hib + OPV; Assigned to Arm(s): Group 3 - BRV-PV Lot C | Intervention Type: BIOLOGICAL; Name: ROTARIX + DPT-HepB-Hib + OPV; Assigned to Arm(s): Group 4 - ROTARIX
D: Arm Label: Liq_A Group; Type: EXPERIMENTAL; Interventions: Biological: HRV PCV-free liquid vaccine | Arm Label: Liq_B Group; Type: EXPERIMENTAL; Interventions: Biological: HRV PCV-free liquid vaccine | Arm Label: Liq_C Group; Type: EXPERIMENTAL; Interventions: Biological: HRV PCV-free liquid vaccine | Arm Label: Lyo Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Rotarix | Intervention Type: BIOLOGICAL; Name: HRV PCV-free liquid vaccine; Assigned to Arm(s): Liq_A Group, Liq_B Group, Liq_C Group | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Lyo Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Women's Heart Attack Research Program: Stress Ancillary Study; Telephone-Based Stress Management for Women With Myocardial Infarction
Brief Summary: The Women's HARP study is a multi-center study focusing on women with clinical presentation of myocardial infarction (MI). Women will complete stress questionnaires following presentation to the medical center with elevated cardiac enzymes and abnormal electrocardiograms (ECGs). 2 months following MI, participants will be screened for the Stress Ancillary Study and enrolled if an elevated level of perceived stress is reported. After completing baseline assessments, participants will be randomized to Enhanced Usual Care (EUC) or stress management for 8 weeks. Participants will be followed for 6 months.


Options:
A: Intervention Type: BEHAVIORAL; Name: Mindfulness Based Stress Reduction; Assigned to Arm(s): N/A
B: Arm Label: FACT Module Engagement; Type: EXPERIMENTAL; Interventions: Behavioral: FACT Module Engagement | Arm Label: FACT Module Openness; Type: EXPERIMENTAL; Interventions: Behavioral: FACT Module Openness | Arm Label: FACT Module Awareness; Type: EXPERIMENTAL; Interventions: Behavioral: FACT Module Awareness | Intervention Type: BEHAVIORAL; Name: FACT Module Engagement; Assigned to Arm(s): FACT Module Engagement | Intervention Type: BEHAVIORAL; Name: FACT Module Openness; Assigned to Arm(s): FACT Module Openness | Intervention Type: BEHAVIORAL; Name: FACT Module Awareness; Assigned to Arm(s): FACT Module Awareness
C: Arm Label: Enhanced Usual Care (EUC); Type: OTHER; Interventions: Behavioral: Enhanced Usual Care, Diagnostic Test: Actigraph | Arm Label: Stress Management; Type: OTHER; Interventions: Behavioral: Stress Management, Diagnostic Test: Actigraph | Intervention Type: BEHAVIORAL; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care (EUC) | Intervention Type: BEHAVIORAL; Name: Stress Management; Assigned to Arm(s): Stress Management | Intervention Type: DIAGNOSTIC_TEST; Name: Actigraph; Assigned to Arm(s): Enhanced Usual Care (EUC), Stress Management
D: Arm Label: Stress reduction; Type: EXPERIMENTAL; Interventions: Behavioral: Transcendental Meditation | Arm Label: health education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Education | Intervention Type: BEHAVIORAL; Name: Transcendental Meditation; Assigned to Arm(s): Stress reduction | Intervention Type: BEHAVIORAL; Name: Health Education; Assigned to Arm(s): health education

Answer: C